Cao H, Duan L, Zhang Y, Cao J and Zhang K: Current hydrogel advances in physicochemical and biological response-driven biomedical application diversity. Signal Transduct Target Ther. 6(426)2021.PubMed/NCBI View Article : Google Scholar

Munir MU: Nanomedicine penetration to tumor: Challenges, and advanced strategies to tackle this issue. Cancers (Basel). 14(2904)2022.PubMed/NCBI View Article : Google Scholar

Mansoori B, Mohammadi A, Davudian S, Shirjang S and Baradaran B: The different mechanisms of cancer drug resistance: A brief review. Adv Pharm Bull. 7:339–348. 2017.PubMed/NCBI View Article : Google Scholar

Gkretsi V, Stylianou A, Papageorgis P, Polydorou C and Stylianopoulos T: Remodeling components of the tumor microenvironment to enhance cancer therapy. Front Oncol. 5(214)2015.PubMed/NCBI View Article : Google Scholar

Tosca EM, Ronchi D, Facciolo D and Magni P: Replacement, reduction, and refinement of animal experiments in anticancer drug development: The contribution of 3D in vitro cancer models in the drug efficacy assessment. Biomedicines. 11(1058)2023.PubMed/NCBI View Article : Google Scholar

Khalil AS, Jaenisch R and Mooney DJ: Engineered tissues and strategies to overcome challenges in drug development. Adv Drug Deliv Rev. 158:116–139. 2020.PubMed/NCBI View Article : Google Scholar

Booij TH, Price LS and Danen EHJ: 3D cell-based assays for drug screens: Challenges in imaging, image analysis, and high-content analysis. SLAS Discov. 24:615–627. 2019.PubMed/NCBI View Article : Google Scholar

Candini O, Grisendi G, Foppiani EM, Brogli M, Aramini B, Masciale V, Spano C, Petrachi T, Veronesi E, Conte P, et al: A novel 3D in vitro platform for pre-clinical investigations in drug testing, gene therapy, and immuno-oncology. Sci Rep. 9(7154)2019.PubMed/NCBI View Article : Google Scholar

Unger C, Kramer N, Walzl A, Scherzer M, Hengstschläger M and Dolznig H: Modeling human carcinomas: Physiologically relevant 3D models to improve anti-cancer drug development. Adv Drug Deliv Rev. 79-80:50–67. 2014.PubMed/NCBI View Article : Google Scholar

Kelm JM, Lal-Nag M, Sittampalam GS and Ferrer M: Translational in vitro research: Integrating 3D drug discovery and development processes into the drug development pipeline. Drug Discov Today. 24:26–30. 2019.PubMed/NCBI View Article : Google Scholar

Krisnawan VE, Stanley JA, Schwarz JK and DeNardo DG: Tumor microenvironment as a regulator of radiation therapy: New insights into stromal-mediated radioresistance. Cancers (Basel). 12(2916)2020.PubMed/NCBI View Article : Google Scholar

Bonnier F, Keating ME, Wróbel TP, Majzner K, Baranska M, Garcia-Munoz A and Byrne HJ: Cell viability assessment using the Alamar blue assay: A comparison of 2D and 3D cell culture models. Toxicol In Vitro. 29:124–131. 2015.PubMed/NCBI View Article : Google Scholar

Duval K, Grover H, Han LH, Mou Y, Pegoraro AF, Fredberg J and Chen Z: Modeling physiological events in 2D vs. 3D cell culture. Physiology (Bethesda). 32:266–277. 2017.PubMed/NCBI View Article : Google Scholar

Yi HG, Jeong YH, Kim Y, Choi YJ, Moon HE, Park SH, Kang KS, Bae M, Jang J, Youn H, et al: A bioprinted human-glioblastoma-on-a-chip for the identification of patient-specific responses to chemoradiotherapy. Nat Biomed Eng. 3:509–519. 2019.PubMed/NCBI View Article : Google Scholar

Gomez-Roman N, Chong MY, Chahal SK, Caragher SP, Jackson MR, Stevenson KH, Dongre SA and Chalmers AJ: Radiation responses of 2D and 3D glioblastoma cells: A novel, 3D-specific radioprotective role of VEGF/Akt signaling through functional activation of NHEJ. Mol Cancer Ther. 19:575–589. 2020.PubMed/NCBI View Article : Google Scholar

Kalli M and Stylianopoulos T: Toward innovative approaches for exploring the mechanically regulated tumor-immune microenvironment. APL Bioeng. 8(011501)2024.PubMed/NCBI View Article : Google Scholar

Zhou Z, Vessella T, Wang P, Cui F, Wen Q and Zhou HS: Mechanical cues in tumor microenvironment on chip. Biosens Bioelectron X. 14(100376)2023.

Langhans SA: Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front Pharmacol. 9(6)2018.PubMed/NCBI View Article : Google Scholar

Rodrigues J, Heinrich MA, Teixeira LM and Prakash J: 3D in vitro model (R)evolution: Unveiling tumor-stroma interactions. Trends Cancer. 7:249–264. 2021.PubMed/NCBI View Article : Google Scholar

Jensen C and Teng Y: Is it time to start transitioning from 2D to 3D cell culture? Front Mol Biosci. 7(33)2020.PubMed/NCBI View Article : Google Scholar

Gill BJ and West JL: Modeling the tumor extracellular matrix: Tissue engineering tools repurposed towards new frontiers in cancer biology. J Biomech. 47:1969–1978. 2014.PubMed/NCBI View Article : Google Scholar

Wishart G, Gupta P, Schettino G, Nisbet A and Velliou E: 3d tissue models as tools for radiotherapy screening for pancreatic cancer. Br J Radiol. 94(20201397)2021.PubMed/NCBI View Article : Google Scholar

Mukubou H, Tsujimura T, Sasaki R and Ku Y: The role of autophagy in the treatment of pancreatic cancer with gemcitabine and ionizing radiation. Int J Oncol. 37:821–828. 2010.PubMed/NCBI View Article : Google Scholar

Baselet B, Sonveaux P, Baatout S and Aerts A: Pathological effects of ionizing radiation: Endothelial activation and dysfunction. Cell Mol Life Sci. 76:699–728. 2019.PubMed/NCBI View Article : Google Scholar

Baker BM and Chen CS: Deconstructing the third dimension: How 3D culture microenvironments alter cellular cues. J Cell Sci. 125(Pt 13):3015–3024. 2012.PubMed/NCBI View Article : Google Scholar

Kapałczyńska M, Kolenda T, Przybyła W, Zajączkowska M, Teresiak A, Filas V, Ibbs M, Bliźniak R, Łuczewski Ł and Lamperska K: 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. Arch Med Sci. 14:910–919. 2018.PubMed/NCBI View Article : Google Scholar

Riedl A, Schlederer M, Pudelko K, Stadler M, Walter S, Unterleuthner D, Unger C, Kramer N, Hengstschläger M, Kenner L, et al: Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses. J Cell Sci. 130:203–218. 2017.PubMed/NCBI View Article : Google Scholar

Cekanova M and Rathore K: Animal models and therapeutic molecular targets of cancer: Utility and limitations. Drug Des Devel Ther. 8:1911–1921. 2014.PubMed/NCBI View Article : Google Scholar

Horvath P, Aulner N, Bickle M, Davies AM, Nery ED, Ebner D, Montoya MC, Östling P, Pietiäinen V, Price LS, et al: Screening out irrelevant cell-based models of disease. Nat Rev Drug Discov. 15:751–769. 2016.PubMed/NCBI View Article : Google Scholar

Amoedo ND, Obre E and Rossignol R: Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy. Biochim Biophys Acta Bioenerg. 1858:674–685. 2017.PubMed/NCBI View Article : Google Scholar

Kerslake R, Belay B, Panfilov S, Hall M, Kyrou I, Randeva HS, Hyttinen J, Karteris E and Sisu C: Transcriptional landscape of 3D vs. 2D ovarian cancer cell models. Cancers (Basel). 15(3350)2023.PubMed/NCBI View Article : Google Scholar

Zhang B, Korolj A, Lai BFL and Radisic M: Advances in organ-on-a-chip engineering. Nat Rev Mater. 3:257–278. 2018.

Luca AC, Mersch S, Deenen R, Schmidt S, Messner I, Schäfer KL, Baldus SE, Huckenbeck W, Piekorz RP, Knoefel WT, et al: Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines. PLoS One. 8(e59689)2013.PubMed/NCBI View Article : Google Scholar

van Duinen V, Trietsch SJ, Joore J, Vulto P and Hankemeier T: Microfluidic 3D cell culture: From tools to tissue models. Curr Opin Biotechnol. 35:118–126. 2015.PubMed/NCBI View Article : Google Scholar

Antonelli F: 3D cell models in radiobiology: Improving the predictive value of in vitro research. Int J Mol Sci. 24(10620)2023.PubMed/NCBI View Article : Google Scholar

Boucherit N, Gorvel L and Olive D: 3D tumor models and their use for the testing of immunotherapies. Front Immunol. 11(603640)2020.PubMed/NCBI View Article : Google Scholar

Barozzi D and Scielzo C: Emerging strategies in 3D culture models for hematological cancers. Hemasphere. 7(e932)2023.PubMed/NCBI View Article : Google Scholar

Bédard P, Gauvin S, Ferland K, Caneparo C, Pellerin È, Chabaud S and Bolduc S: Innovative human three-dimensional tissue-engineered models as an alternative to animal testing. Bioengineering (Basel). 7(115)2020.PubMed/NCBI View Article : Google Scholar

Li W, Zhou Z, Zhou X, Khoo BL, Gunawan R, Chin YR, Zhang L, Yi C, Guan X and Yang M: 3D biomimetic models to reconstitute tumor microenvironment in vitro: Spheroids, organoids, and Tumor-on-a-chip. Adv Healthc Mater. 12(e2202609)2023.PubMed/NCBI View Article : Google Scholar

Barbosa MAG, Xavier CPR, Pereira RF, Petrikaitė V and Vasconcelos MH: 3D cell culture models as recapitulators of the tumor microenvironment for the screening of anti-cancer drugs. Cancers (Basel). 14(190)2021.PubMed/NCBI View Article : Google Scholar

Amaral RLF, Miranda M, Marcato PD and Swiech K: Comparative analysis of 3D bladder tumor spheroids obtained by forced floating and hanging drop methods for drug screening. Front Physiol. 8(605)2017.PubMed/NCBI View Article : Google Scholar

Strobel HA, Calamari EL, Alphonse B, Hookway TA and Rolle MW: Fabrication of custom agarose wells for cell seeding and tissue ring self-assembly using 3D-Printed Molds. J Vis Exp. (134)(56618)2018.PubMed/NCBI View Article : Google Scholar

Rauh J, Milan F, Günther KP and Stiehler M: Bioreactor systems for bone tissue engineering. Tissue Eng Part B Rev. 17:263–280. 2011.PubMed/NCBI View Article : Google Scholar

Antoni D, Burckel H, Josset E and Noel G: Three-dimensional cell culture: A breakthrough in vivo. Int J Mol Sci. 16:5517–5527. 2015.PubMed/NCBI View Article : Google Scholar

Zhang S, Liu P, Chen L, Wang Y, Wang Z and Zhang B: The effects of spheroid formation of adipose-derived stem cells in a microgravity bioreactor on stemness properties and therapeutic potential. Biomaterials. 41:15–25. 2015.PubMed/NCBI View Article : Google Scholar

Chaicharoenaudomrung N, Kunhorm P and Noisa P: Three-dimensional cell culture systems as an in vitro platform for cancer and stem cell modeling. World J Stem Cells. 11:1065–1083. 2019.PubMed/NCBI View Article : Google Scholar

Marques IA, Fernandes C, Tavares NT, Pires AS, Abrantes AM and Botelho MF: Magnetic-based human tissue 3D cell culture: A systematic review. Int J Mol Sci. 23(12681)2022.PubMed/NCBI View Article : Google Scholar

Patra B, Peng CC, Liao WH, Lee CH and Tung YC: Drug testing and flow cytometry analysis on a large number of uniform sized tumor spheroids using a microfluidic device. Sci Rep. 6(21061)2016.PubMed/NCBI View Article : Google Scholar

Zanoni M, Piccinini F, Arienti C, Zamagni A, Santi S, Polico R, Bevilacqua A and Tesei A: 3D tumor spheroid models for in vitro therapeutic screening: A systematic approach to enhance the biological relevance of data obtained. Sci Rep. 6(19103)2016.PubMed/NCBI View Article : Google Scholar

Pinto B, Henriques AC, Silva PMA and Bousbaa H: Three-dimensional spheroids as in vitro preclinical models for cancer research. Pharmaceutics. 12(1186)2020.PubMed/NCBI View Article : Google Scholar

Rodrigues DB, Reis RL and Pirraco RP: Modelling the complex nature of the tumor microenvironment: 3D tumor spheroids as an evolving tool. J Biomed Sci. 31(13)2024.PubMed/NCBI View Article : Google Scholar

Vakhshiteh F, Bagheri Z, Soleimani M, Ahvaraki A, Pournemat P, Alavi SE and Madjd Z: Heterotypic tumor spheroids: A platform for nanomedicine evaluation. J Nanobiotechnology. 21(249)2023.PubMed/NCBI View Article : Google Scholar

Jiang X, Oyang L, Peng Q, Liu Q, Xu X, Wu N, Tan S, Yang W, Han Y, Lin J, et al: Organoids: opportunities and challenges of cancer therapy. Front Cell Dev Biol. 11(1232528)2023.PubMed/NCBI View Article : Google Scholar

Hou X, Du C, Lu L, Yuan S, Zhan M, You P and Du H: Opportunities and challenges of patient-derived models in cancer research: Patient-derived xenografts, patient-derived organoid and patient-derived cells. World J Surg Oncol. 20(37)2022.PubMed/NCBI View Article : Google Scholar

Qu J, Kalyani FS, Liu L, Cheng T and Chen L: Tumor organoids: Synergistic applications, current challenges, and future prospects in cancer therapy. Cancer Commun (Lond). 41:1331–1353. 2021.PubMed/NCBI View Article : Google Scholar

Idrisova KF, Simon HU and Gomzikova MO: Role of patient-derived models of cancer in translational oncology. Cancers (Basel). 15(139)2023.PubMed/NCBI View Article : Google Scholar

Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, et al: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nat Commun. 12(5086)2021.PubMed/NCBI View Article : Google Scholar

Tharehalli U, Svinarenko M and Lechel A: Remodelling and improvements in organoid technology to study liver carcinogenesis in a dish. Stem Cells Int. 2019(3831213)2019.PubMed/NCBI View Article : Google Scholar

Yip S, Wang N and Sugimura R: Give them vasculature and immune cells: How to fill the gap of organoids. Cells Tissues Organs. 212:369–382. 2023.PubMed/NCBI View Article : Google Scholar

Zhang S, Wan Z and Kamm RD: Vascularized organoids on a chip: Strategies for engineering organoids with functional vasculature. Lab Chip. 21:473–488. 2021.PubMed/NCBI View Article : Google Scholar

Bar-Ephraim YE, Kretzschmar K, Asra P, de Jongh E, Boonekamp KE, Drost J, van Gorp J, Pronk A, Smakman N, Gan I, et al: Modelling cancer immunomodulation using epithelial organoid cultures. bioRxiv, p377655, 2018.

Kim J, Koo BK and Knoblich JA: Human organoids: Model systems for human biology and medicine. Nat Rev Mol Cell Biol. 21:571–584. 2020.PubMed/NCBI View Article : Google Scholar

Ferreira LP, Gaspar VM and Mano JF: Design of spherically structured 3D in vitro tumor models-Advances and prospects. Acta Biomater. 75:11–34. 2018.PubMed/NCBI View Article : Google Scholar

Unnikrishnan K, Thomas LV and Ram Kumar RM: Advancement of scaffold-based 3D cellular models in cancer tissue engineering: An update. Front Oncol. 11(733652)2021.PubMed/NCBI View Article : Google Scholar

Sun L, Wang X, He Y, Chen B, Shan B, Yang J, Wang R, Zeng X, Li J, Tan H and Liang R: Polyurethane scaffold-based 3D lung cancer model recapitulates in vivo tumor biological behavior for nanoparticulate drug screening. Regen Biomater. 10(rbad091)2023.PubMed/NCBI View Article : Google Scholar

Li X, Shan J, Chen X, Cui H, Wen G and Yu Y: Decellularized diseased tissues: Current state-of-the-art and future directions. MedComm (2020). 4(e399)2023.PubMed/NCBI View Article : Google Scholar

Zhang CY, Fu CP, Li XY, Lu XC, Hu LG, Kankala RK, Wang SB and Chen AZ: Three-dimensional bioprinting of decellularized extracellular matrix-based bioinks for tissue engineering. Molecules. 27(3442)2022.PubMed/NCBI View Article : Google Scholar

Habanjar O, Diab-Assaf M, Caldefie-Chezet F and Delort L: 3D cell culture systems: Tumor application, advantages, and disadvantages. Int J Mol Sci. 22(12200)2021.PubMed/NCBI View Article : Google Scholar

Abuwatfa WH, Pitt WG and Husseini GA: Scaffold-based 3D cell culture models in cancer research. J Biomed Sci. 31(7)2024.PubMed/NCBI View Article : Google Scholar

Shivalkar S and Singh S: Solid freeform techniques application in bone tissue engineering for scaffold fabrication. Tissue Eng Regen Med. 14:187–200. 2017.PubMed/NCBI View Article : Google Scholar

Suri S, Han LH, Zhang W, Singh A, Chen S and Schmidt CE: Solid freeform fabrication of designer scaffolds of hyaluronic acid for nerve tissue engineering. Biomed Microdevices. 13:983–993. 2011.PubMed/NCBI View Article : Google Scholar

Tony A, Badea I, Yang C, Liu Y, Wells G, Wang K, Yin R, Zhang H and Zhang W: The additive manufacturing approach to polydimethylsiloxane (PDMS) microfluidic devices: Review and future directions. Polymers (Basel). 15(1926)2023.PubMed/NCBI View Article : Google Scholar

Anthon SG and Valente KP: Vascularization strategies in 3D cell culture models: From scaffold-free models to 3D bioprinting. Int J Mol Sci. 23(14582)2022.PubMed/NCBI View Article : Google Scholar

Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY and Ingber DE: Reconstituting organ-level lung functions on a chip. Science. 328:1662–1668. 2010.PubMed/NCBI View Article : Google Scholar

Wang Y, Gao Y, Pan Y, Zhou D, Liu Y, Yin Y, Yang J, Wang Y and Song Y: Emerging trends in organ-on-a-chip systems for drug screening. Acta Pharm Sin B. 13:2483–2509. 2023.PubMed/NCBI View Article : Google Scholar

Li Z, Hui J, Yang P and Mao H: Microfluidic organ-on-a-chip system for disease modeling and drug development. Biosensors (Basel). 12(370)2022.PubMed/NCBI View Article : Google Scholar

Vargas R, Egurbide-Sifre A and Medina L: Organ-on-a-chip systems for new drugs development. ADMET DMPK. 9:111–141. 2021.PubMed/NCBI View Article : Google Scholar

Tajeddin A and Mustafaoglu N: Design and fabrication of organ-on-chips: Promises and challenges. Micromachines (Basel). 12(1443)2021.PubMed/NCBI View Article : Google Scholar

Si L, Bai H, Rodas M, Cao W, Oh CY, Jiang A, Moller R, Hoagland D, Oishi K, Horiuchi S, et al: A humanairway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics. Nat Biomed Eng. 5:815–829. 2021.PubMed/NCBI View Article : Google Scholar

Bai H, Si L, Jiang A, Belgur C, Zhai Y, Plebani R, Oh CY, Rodas M, Patil A, Nurani A, et al: Mechanical control of innate immune responses against viral infection revealed in a human lung alveolus chip. Nat Commun. 13(1928)2022.PubMed/NCBI View Article : Google Scholar

Plebani R, Bai H, Si L, Li J, Zhang C and Romano M: 3D lung tissue models for studies on SARS-CoV-2 pathophysiology and therapeutics. Int J Mol Sci. 23(10071)2022.PubMed/NCBI View Article : Google Scholar

Plebani R, Potla R, Soong M, Bai H, Izadifar Z, Jiang A, Travis RN, Belgur C, Dinis A, Cartwright MJ, et al: Modeling pulmonary cystic fibrosis in a human lung airway-on-a-chip. J Cyst Fibros. 21:606–615. 2022.PubMed/NCBI View Article : Google Scholar

Bein A, Fadel CW, Swenor B, Cao W, Powers RK, Camacho DM, Naziripour A, Parsons A, LoGrande N, Sharma S, et al: Nutritional deficiency in an intestine-on-a-chip recapitulates injury hallmarks associated with environmental enteric dysfunction. Nat Biomed Eng. 6:1236–1247. 2022.PubMed/NCBI View Article : Google Scholar

Ewart L, Apostolou A, Briggs SA, Carman CV, Chaff JT, Heng AR, Jadalannagari S, Janardhanan J, Jang KJ, Joshipura SR, et al: Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology. Commun Med (Lond). 2(154)2022.PubMed/NCBI View Article : Google Scholar

Benam KH, Novak R, Nawroth J, Hirano-Kobayashi M, Ferrante TC, Choe Y, Prantil-Baun R, Weaver JC, Bahinski A, Parker KK and Ingber DE: Matched-comparative modeling of normal and diseased human airway responses using a microengineered breathing lung chip. Cell Syst. 3:456–466.e4. 2016.PubMed/NCBI View Article : Google Scholar

Zommiti M, Connil N, Tahrioui A, Groboillot A, Barbey C, Konto-Ghiorghi Y, Lesouhaitier O, Chevalier S and Feuilloley MGJ: Organs-on-chips platforms are everywhere: A zoom on biomedical investigation. Bioengineering (Basel). 9(646)2022.PubMed/NCBI View Article : Google Scholar

Monteduro AG, Rizzato S, Caragnano G, Trapani A, Giannelli G and Maruccio G: Organs-on-chips technologies-A guide from disease models to opportunities for drug development. Biosens Bioelectron. 231(115271)2023.PubMed/NCBI View Article : Google Scholar

Zhao Y, Kankala RK, Wang SB and Chen AZ: Multi-organs-on-chips: Towards long-term biomedical investigations. Molecules. 24(675)2019.PubMed/NCBI View Article : Google Scholar

R N, Aggarwal A, Sravani AB, Mallya P and Lewis S: Organ-on-a-chip: An emerging research platform. Organogenesis. 19(2278236)2023.PubMed/NCBI View Article : Google Scholar

Mauriac H, Pannetier C and Casquillas GV: Organs on Chip Review. Elveflow. Available from: https://www.elveflow.com/microfluidic-reviews/organs-on-chip-3d-cell-culture/organs-chip-review/.

Sun W, Luo Z, Lee J, Kim HJ, Lee K, Tebon P, Feng Y, Dokmeci MR, Sengupta S and Khademhosseini A: Organ-on-a-chip for cancer and immune organs modeling. Adv Healthc Mater. 8(1801363)2019.PubMed/NCBI View Article : Google Scholar

van den Berg A, Mummery CL, Passier R and van der Meer AD: Personalised organs-on-chips: Functional testing for precision medicine. Lab Chip. 19:198–205. 2019.PubMed/NCBI View Article : Google Scholar

Wu J, Dong M, Rigatto C, Liu Y and Lin F: Lab-on-chip technology for chronic disease diagnosis. NPJ Digit Med. 1(7)2018.PubMed/NCBI View Article : Google Scholar

Glieberman AL, Pope BD, Zimmerman JF, Liu Q, Ferrier JP, Kenty JHR, Schrell AM, Mukhitov N, Shores KL, Tepole AB, et al: Synchronized stimulation and continuous insulin sensing in a microfluidic human Islet on a chip designed for scalable manufacturing. Lab Chip. 19:2993–3010. 2019.PubMed/NCBI View Article : Google Scholar

Wang D, Cong Y, Deng Q, Han X, Zhang S, Zhao L, Luo Y and Zhang X: Physiological and disease models of respiratory system based on organ-on-a-chip technology. Micromachines (Basel). 12(1106)2021.PubMed/NCBI View Article : Google Scholar

Kimura H, Sakai Y and Fujii T: Organ/body-on-a-chip based on microfluidic technology for drug discovery. Drug Metab Pharmacokinet. 33:43–48. 2018.PubMed/NCBI View Article : Google Scholar

Lu RXZ and Radisic M: Organ-on-a-chip platforms for evaluation of environmental nanoparticle toxicity. Bioact Mater. 6:2801–2819. 2021.PubMed/NCBI View Article : Google Scholar

Wikswo JP, Curtis EL, Eagleton ZE, Evans BC, Kole A, Hofmeister LH and Matloff WJ: Scaling and systems biology for integrating multiple organs-on-a-chip. Lab Chip. 13:3496–511. 2013.PubMed/NCBI View Article : Google Scholar

Bang S, Jeong S, Choi N and Kim HN: Brain-on-a-chip: A history of development and future perspective. Biomicrofluidics. 13(051301)2019.PubMed/NCBI View Article : Google Scholar

Mao M, Bei HP, Lam CH, Chen P, Wang S, Chen Y, He J and Zhao X: Human-on-leaf-chip: A biomimetic vascular system integrated with chamber-specific organs. Small. 16(e2000546)2020.PubMed/NCBI View Article : Google Scholar

Ramadan Q and Gijs MA: In vitro micro-physiological models for translational immunology. Lab Chip. 15:614–636. 2015.PubMed/NCBI View Article : Google Scholar

Mandrycky CJ, Howard CC, Rayner SG, Shin YJ and Zheng Y: Organ-on-a-chip systems for vascular biology. J Mol Cell Cardiol. 159:1–13. 2021.PubMed/NCBI View Article : Google Scholar

Chen Y, Gao D, Wang Y, Lin S and Jiang Y: A novel 3D breast-cancer-on-chip platform for therapeutic evaluation of drug delivery systems. Anal Chim Acta. 1036:97–106. 2018.PubMed/NCBI View Article : Google Scholar

Danku AE, Dulf EH, Braicu C, Jurj A and Berindan-Neagoe I: Organ-on-a-chip: A survey of technical results and problems. Front Bioeng Biotechnol. 10(840674)2022.PubMed/NCBI View Article : Google Scholar

de Haan L, Suijker J, van Roey R, Berges N, Petrova E, Queiroz K, Strijker W, Olivier T, Poeschke O, Garg S and van den Broek LJ: A microfluidic 3D endothelium-on-a-chip model to study transendothelial migration of T cells in health and disease. Int J Mol Sci. 22(8234)2021.PubMed/NCBI View Article : Google Scholar

van Duinen V, van den Heuvel A, Trietsch SJ, Lanz HL, van Gils JM, van Zonneveld AJ, Vulto P and Hankemeier T: 96 perfusable blood vessels to study vascular permeability in vitro. Sci Rep. 7(18071)2017.PubMed/NCBI View Article : Google Scholar

Trietsch SJ, Naumovska E, Kurek D, Setyawati MC, Vormann MK, Wilschut KJ, Lanz HL, Nicolas A, Ng CP, Joore J, et al: Membrane-free culture and real-time barrier integrity assessment of perfused intestinal epithelium tubes. Nat Commun. 8(262)2017.PubMed/NCBI View Article : Google Scholar

Ozer LY, Fayed HS, Ericsson J and Al Haj Zen A: Development of a cancer metastasis-on-chip assay for high throughput drug screening. Front Oncol. 13(1269376)2024.PubMed/NCBI View Article : Google Scholar

Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, et al: Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 8:935–942. 2002.PubMed/NCBI

Cohen P, Cross D and Jänne PA: Kinase drug discovery 20 years after imatinib: Progress and future directions. Nat Rev Drug Discov. 20:551–569. 2021.PubMed/NCBI View Article : Google Scholar

Blay JY, Kang YK, Nishida T and von Mehren M: Gastrointestinal stromal tumours. Nat Rev Dis Primer. 7(22)2021.PubMed/NCBI View Article : Google Scholar

Reita D, Pabst L, Pencreach E, Guérin E, Dano L, Rimelen V, Voegeli AC, Vallat L, Mascaux C and Beau-Faller M: Molecular mechanism of EGFR-TKI resistance in EGFR-mutated non-small cell lung cancer: Application to biological diagnostic and monitoring. Cancers (Basel). 13(4926)2021.PubMed/NCBI View Article : Google Scholar

Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG and Kolenko VM: Resistance to systemic therapies in clear cell renal cell carcinoma: Mechanisms and Management Strategies. Mol Cancer Ther. 17:1355–1364. 2018.PubMed/NCBI View Article : Google Scholar

He J, Huang Z, Han L, Gong Y and Xie C: Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review). Int J Oncol. 59(90)2021.PubMed/NCBI View Article : Google Scholar

Araki T, Kanda S, Horinouchi H and Ohe Y: Current treatment strategies for EGFR-mutated non-small cell lung cancer: From first line to beyond osimertinib resistance. Jpn J Clin Oncol. 53:547–561. 2023.PubMed/NCBI View Article : Google Scholar

Yoshifuji K and Sasaki K: Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia. Front Oncol. 12(1021662)2022.PubMed/NCBI View Article : Google Scholar

Li Y, Mao T, Wang J, Zheng H, Hu Z, Cao P, Yang S, Zhu L, Guo S, Zhao X, et al: Toward the next generation EGFR inhibitors: An overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer. Cell Commun Signal. 21(71)2023.PubMed/NCBI View Article : Google Scholar

Kumar S and Agrawal R: Next generation tyrosine kinase inhibitor (TKI): Afatinib. Recent Pat Anticancer Drug Discov. 9:382–393. 2014.PubMed/NCBI View Article : Google Scholar

Blaquier JB, Ortiz-Cuaran S, Ricciuti B, Mezquita L, Cardona AF and Recondo G: Tackling osimertinib resistance in EGFR-mutant non-small cell lung cancer. Clin Cancer Res. 29:3579–3591. 2023.PubMed/NCBI View Article : Google Scholar

Du X, Yang B, An Q, Assaraf YG, Cao X and Xia J: Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. Innovation (Camb). 2(100103)2021.PubMed/NCBI View Article : Google Scholar

Iqbal N and Iqbal N: Imatinib: A breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014(357027)2014.PubMed/NCBI View Article : Google Scholar

Sacha T: Imatinib in chronic myeloid leukemia: An overview. Mediterr J Hematol Infect Dis. 6(e2014007)2014.PubMed/NCBI View Article : Google Scholar

Lopes LF and Bacchi CE: Imatinib treatment for gastrointestinal stromal tumour (GIST). J Cell Mol Med. 14:42–50. 2010.PubMed/NCBI View Article : Google Scholar

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, et al: Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 376:917–927. 2017.PubMed/NCBI View Article : Google Scholar

Gollob JA, Wilhelm S, Carter C and Kelley SL: Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol. 33:392–406. 2006.PubMed/NCBI View Article : Google Scholar

Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M and Bukowski RM: Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol. 23 (Suppl 16)(LBA451)2005.

Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Wellik LE, Witzig TE, Rajkumar SV, Adjei AA and Kumar S: Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene. 29:1190–1202. 2010.PubMed/NCBI View Article : Google Scholar

Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140. 2008.PubMed/NCBI View Article : Google Scholar

Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M and Carter C: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66:11851–11858. 2006.PubMed/NCBI View Article : Google Scholar

Pagano M, Sierra NM, Panebianco M, Rossi G, Gnoni R, Bisagni G and Boni C: Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations. Anticancer Res. 34:5105–5110. 2014.PubMed/NCBI

Adnane L, Trail PA, Taylor I and Wilhelm SM: Sorafenib (BAY 43-9006, Nexavar®), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 407:597–612. 2006.PubMed/NCBI View Article : Google Scholar

Woo HY and Heo J: Sorafenib in liver cancer. Expert Opin Pharmacother. 13:1059–1067. 2012.PubMed/NCBI View Article : Google Scholar

Zhu YJ, Zheng B, Wang HY and Chen L: New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 38:614–622. 2017.PubMed/NCBI View Article : Google Scholar

Cheng Z, Wei-Qi J and Jin D: New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. Biochim Biophys Acta Rev Cancer. 1874(188382)2020.PubMed/NCBI View Article : Google Scholar

Gauthier A and Ho M: Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol Res. 43:147–154. 2013.PubMed/NCBI View Article : Google Scholar

Porta C, Paglino C, Imarisio I and Ferraris E: Sorafenib tosylate in advanced kidney cancer: Past, present and future. Anticancer Drugs. 20:409–415. 2009.PubMed/NCBI View Article : Google Scholar

Larkin JM and Eisen T: Renal cell carcinoma and the use of sorafenib. Ther Clin Risk Manag. 2:87–98. 2006.PubMed/NCBI

Bukowski R, Cella D, Gondek K and Escudier B: Sorafenib TARGETs Clinical Trial Group. Effects of sorafenib on symptoms and quality of life: Results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol. 30:220–227. 2007.PubMed/NCBI View Article : Google Scholar

Szczylik C, Cella D, Eisen T, Shah S, Laferriere N, Scheuring U and Escudier BJ: Comparison of kidney cancer symptoms and quality of life (QoL) in renal cell cancer (RCC) patients (pts) receiving sorafenib vs interferon-α (IFN). J Clin Oncol. 26 (Suppl 15)(S9603)2008.

Strumberg D: Sorafenib for the treatment of renal cancer. Expert Opin Pharmacother. 13:407–419. 2012.PubMed/NCBI View Article : Google Scholar

Capdevila J, Iglesias L, Halperin I, Segura Á, Martínez-Trufero J, Vaz MÁ, Corral J, Obiols G, Grande E, Grau JJ and Tabernero J: Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer. 19:209–216. 2012.PubMed/NCBI View Article : Google Scholar

Pitoia F and Jerkovich F: Selective use of sorafenib in the treatment of thyroid cancer. Drug Des Devel Ther. 10:1119–1131. 2016.PubMed/NCBI View Article : Google Scholar

Thomas L, Lai SY, Dong W, Feng L, Dadu R, Regone RM and Cabanillas ME: Sorafenib in metastatic thyroid cancer: A systematic review. Oncologist. 19:251–258. 2014.PubMed/NCBI View Article : Google Scholar

Chen P, Wang J, Yao Y, Qu Y, Ji M and Hou P: . Targeting DUSP5 suppresses malignant phenotypes of BRAF-mutant thyroid cancer cells and improves their response to sorafenib. Endocrine. 85:1268–1277. 2024.PubMed/NCBI View Article : Google Scholar

Pereira A, Parra D, Alvarez M and Rincon O: Response to sorafenib in a locally advanced oncocytic cell carcinoma of the thyroid. BMJ Case Rep. 17(e257738)2024.PubMed/NCBI View Article : Google Scholar

Yun KM and Cohen EEW: An era of advances in systemic therapies for advanced thyroid cancer. JCO Oncol Pract. 20:899–906. 2024.PubMed/NCBI View Article : Google Scholar

Ek F, Blom K, Selvin T, Rudfeldt J, Andersson C, Senkowski W, Brechot C, Nygren P, Larsson R, Jarvius M and Fryknäs M: Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma. Sci Rep. 12(8943)2022.PubMed/NCBI View Article : Google Scholar

Bielecka ZF, Malinowska A, Brodaczewska KK, Klemba A, Kieda C, Krasowski P, Grzesiuk E, Piwowarski J, Czarnecka AM and Szczylik C: Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells. Cell Biosci. 7(71)2017.PubMed/NCBI View Article : Google Scholar

Yueh PF, Chiang CS, Tsai IJ, Tseng YL, Chen HR, Lan KL and Hsu FT: A multifunctional PEGylated liposomal-encapsulated sunitinib enhancing autophagy, immunomodulation, and safety in renal cell carcinoma. J Nanobiotechnology. 22(459)2024.PubMed/NCBI View Article : Google Scholar

Yan XQ, Ye MJ, Zou Q, Chen P, He ZS, Wu B, He DL, He CH, Xue XY, Ji ZG, et al: Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. Ann Oncol. 35:190–199. 2024.PubMed/NCBI View Article : Google Scholar

Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, et al: Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: Final prespecified overall survival analysis of CLEAR, a Phase III Study. J Clin Oncol. 42:1222–1228. 2024.PubMed/NCBI View Article : Google Scholar

Uhlig A, Bergmann L, Bögemann M, Fischer T, Goebell PJ, Leitsmann M, Reichert M, Rink M, Schlack K, Trojan L, et al: Sunitinib for metastatic renal cell carcinoma: Real-world data from the STAR-TOR registry and detailed literature review. Urol Int. 108:198–210. 2024.PubMed/NCBI View Article : Google Scholar

Heinrich MC, Jones RL, George S, Gelderblom H, Schöffski P, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, et al: Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. Nat Med. 30:498–506. 2024.PubMed/NCBI View Article : Google Scholar

Li J, Zhang J, Zhang Y, Qiu H, Zhou Y, Zhou Y, Zhang X, Zhou Y, Zhu Y, Li Y, et al: Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China. Eur J Cancer. 196(113439)2024.PubMed/NCBI View Article : Google Scholar

Giraud EL, Westerdijk K, van der Kleij MBA, Guchelaar NAD, Meertens M, Bleckman RF, Rieborn A, Mohammadi M, Roets E, Mathijssen RHJ, et al: Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: The effect of TDM-guided dose optimization on clinical outcomes. ESMO Open. 9(103477)2024.PubMed/NCBI View Article : Google Scholar

Hopkins TG, Marples M and Stark D: Sunitinib in the management of gastrointestinal stromal tumours (GISTs). Eur J Surg Oncol. 34:844–850. 2008.PubMed/NCBI View Article : Google Scholar

Mulet-Margalef N and Garcia-del-Muro X: Sunitinib in the treatment of gastrointestinal stromal tumor: Patient selection and perspectives. OncoTargets Ther. 9:7573–7582. 2016.PubMed/NCBI View Article : Google Scholar

Le Tourneau C, Raymond E and Faivre S: Sunitinib: A novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther Clin Risk Manag. 3:341–348. 2007.PubMed/NCBI View Article : Google Scholar

Raymond E, Hammel P, Dreyer C, Maatescu C, Hentic O, Ruszniewski P and Faivre S: Sunitinib in pancreatic neuroendocrine tumors. Target Oncol. 7:117–125. 2012.PubMed/NCBI View Article : Google Scholar

Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, et al: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 26:3403–3410. 2008.PubMed/NCBI View Article : Google Scholar

Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 364:501–513. 2011.PubMed/NCBI View Article : Google Scholar

Valle JW, Borbath I, Rosbrook B, Fernandez K and Raymond E: Sunitinib in patients with pancreatic neuroendocrine tumors: Update of safety data. Future Oncol. 15:1219–1230. 2019.PubMed/NCBI View Article : Google Scholar

Polena H, Creuzet J, Dufies M, Sidibé A, Khalil-Mgharbel A, Salomon A, Deroux A, Quesada JL, Roelants C, Filhol O, et al: The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: A marker of response to antitumoural treatment in metastatic renal cell carcinoma. Br J Cancer. 118:1179–1188. 2018.PubMed/NCBI View Article : Google Scholar

Rausch M, Rutz A, Allard PM, Delucinge-Vivier C, Docquier M, Dormond O, Wolfender JL and Nowak-Sliwinska P: Molecular and functional analysis of sunitinib-resistance induction in human renal cell carcinoma cells. Int J Mol Sci. 22(6467)2021.PubMed/NCBI View Article : Google Scholar

Stratmann AT, Fecher D, Wangorsch G, Göttlich C, Walles T, Walles H, Dandekar T, Dandekar G and Nietzer SL: Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model. Mol Oncol. 8:351–365. 2014.PubMed/NCBI View Article : Google Scholar

Liu B, Chen D, Chen S, Saber A and Haisma H: Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer. Biochem Pharmacol. 178(114095)2020.PubMed/NCBI View Article : Google Scholar

Jacobi N, Seeboeck R, Hofmann E, Schweiger H, Smolinska V, Mohr T, Boyer A, Sommergruber W, Lechner P, Pichler-Huebschmann C, et al: Organotypic three-dimensional cancer cell cultures mirror drug responses in vivo: Lessons learned from the inhibition of EGFR signaling. Oncotarget. 8:107423–107440. 2017.PubMed/NCBI View Article : Google Scholar

Zheng Q, Dong H, Mo J, Zhang Y, Huang J, Ouyang S, Shi S, Zhu K, Qu X, Hu W, et al: A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics. 11:824–840. 2021.PubMed/NCBI View Article : Google Scholar

Hoque M, Elmaghrabi YA, Köse M, Beevi SS, Jose J, Meneses-Salas E, Blanco-Muñoz P, Conway JRW, Swarbrick A, Timpson P, et al: Annexin A6 improves anti-migratory and anti-invasive properties of tyrosine kinase inhibitors in EGFR overexpressing human squamous epithelial cells. FEBS J. 287:2961–2978. 2020.PubMed/NCBI View Article : Google Scholar

Fu C, Dong J, Zhang J, Li X, Zuo S, Zhang H, Gao S and Chen L: Using three-dimensional model-based tumour volume change to predict the symptom improvement in patients with renal cell cancer. 3 Biotech. 14(148)2024.PubMed/NCBI View Article : Google Scholar

Liu Y, Dai X, Jiang S, Qahar M, Fang C, Guo D, Wang L, Ma S and Huang L: Targeted Co-delivery of gefitinib and rapamycin by aptamer-modified nanoparticles overcomes EGFR-TKI Resistance in NSCLC via Promoting Autophagy. Int J Mol Sci. 23(8025)2022.PubMed/NCBI View Article : Google Scholar

Kim D, Bach DH, Fan YH, Luu TT, Hong JY, Park HJ and Lee SK: AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells. Cell Death Dis. 10(361)2019.PubMed/NCBI View Article : Google Scholar

Hou R, Li X, Xiong J, Shen T, Yu W, Schwartz LH, Zhao B, Zhao J and Fu X: Predicting tyrosine kinase inhibitor treatment response in stage IV lung adenocarcinoma patients with EGFR mutation using model-based deep transfer learning. Front Oncol. 11(679764)2021.PubMed/NCBI View Article : Google Scholar

Ko J, Meyer AN, Haas M and Donoghue DJ: Characterization of FGFR signaling in prostate cancer stem cells and inhibition via TKI treatment. Oncotarget. 12:22–36. 2021.PubMed/NCBI View Article : Google Scholar

Kim SY, Kim SM, Lim S, Lee JY, Choi SJ, Yang SD, Yun MR, Kim CG, Gu SR, Park C, et al: Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma. Clin Cancer Res. 27:4397–4409. 2021.PubMed/NCBI View Article : Google Scholar

Darré H, Masson P, Nativel A, Villain L, Lefaudeux D, Couty C, Martin B, Jacob E, Duruisseaux M, Palgen JL, et al: Comparing the efficacy of two generations of EGFR-TKIs: An integrated drug-disease mechanistic model approach in EGFR-mutated lung adenocarcinoma. Biomedicines. 12(704)2024.PubMed/NCBI View Article : Google Scholar

Zhao X, Zhang X, Chen H, Bao H, Wu X, Wang H, Bao H, Pang J, Wang S and Wang J: Mechanisms of resistance to tyrosine kinase inhibitors in ROS1 fusion-positive nonsmall cell lung cancer. Clin Chem. 70:629–641. 2024.PubMed/NCBI View Article : Google Scholar

Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W and Kunz-Schughart LA: Multicellular tumor spheroids: An underestimated tool is catching up again. J Biotechnol. 148:3–15. 2010.PubMed/NCBI View Article : Google Scholar

Wenzel C, Riefke B, Gründemann S, Krebs A, Christian S, Prinz F, Osterland M, Golfier S, Räse S, Ansari N, et al: 3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions. Exp Cell Res. 323:131–143. 2014.PubMed/NCBI View Article : Google Scholar

Imamura Y, Mukohara T, Shimono Y, Funakoshi Y, Chayahara N, Toyoda M, Kiyota N, Takao S, Kono S, Nakatsura T and Minami H: Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer. Oncol Rep. 33:1837–1843. 2015.PubMed/NCBI View Article : Google Scholar

Hashimoto K, Nishimura S, Ito T, Oka N, Kakinoki R and Akagi M: Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma. Eur J Histochem. 66(3377)2022.PubMed/NCBI View Article : Google Scholar

Leeper AD, Farrell J, Williams LJ, Thomas JS, Dixon JM, Wedden SE, Harrison DJ and Katz E: Determining tamoxifen sensitivity using primary breast cancer tissue in collagen-based three-dimensional culture. Biomaterials. 33:907–915. 2012.PubMed/NCBI View Article : Google Scholar

Andolfi C, Bartolini C, Morales E, Gündoğdu B, Puhr M, Guzman J, Wach S, Taubert H, Aigner A, Eder IE, et al: MED12 and CDK8/19 modulate androgen receptor activity and enzalutamide response in prostate cancer. Endocrinology. 165(bqae114)2024.PubMed/NCBI View Article : Google Scholar

Jenkins RW, Barbie DA and Flaherty KT: Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 118:9–16. 2018.PubMed/NCBI View Article : Google Scholar

Hasin Y, Seldin M and Lusis A: Multi-omics approaches to disease. Genome Biol. 18(83)2017.PubMed/NCBI View Article : Google Scholar

Libbrecht MW and Noble WS: Machine learning applications in genetics and genomics. Nat Rev Genet. 16:321–332. 2015.PubMed/NCBI View Article : Google Scholar

Wang H, Brown PC, Chow ECY, Ewart L, Ferguson SS, Fitzpatrick S, Freedman BS, Guo GL, Hedrich W, Heyward S, et al: 3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration. Clin Transl Sci. 14:1659–1680. 2021.PubMed/NCBI View Article : Google Scholar